Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Rapid antigen testing as a reactive public health response to surges in SARS-CoV-2 outbreak risk in healthcare settings

View ORCID ProfileDavid R. M. Smith, Audrey Duval, Jean Ralph Zahar, Lulla Opatowski, Laura Temime
doi: https://doi.org/10.1101/2021.08.13.21261968
David R. M. Smith
1Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France
2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France
3Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David R. M. Smith
  • For correspondence: davidrobertmundysmith@gmail.com
Audrey Duval
1Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France
2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France
4IAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Ralph Zahar
4IAME, UMR 1137, Université Paris 13, Sorbonne Paris Cité, France
5Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du Risque Infectieux, Groupe Hospitalier Paris Seine Saint-Denis, AP-HP, Bobigny, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lulla Opatowski
1Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France
2Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France
3Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Temime
3Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France
6PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Surges in community SARS-CoV-2 incidence increase risk of importation and subsequent transmission in healthcare facilities. Antigen rapid diagnostic testing (Ag-RDT) is widely used for population screening, but its health and economic benefits as a reactive intervention in healthcare settings are unclear.

Methods We used stochastic, individual-based modelling to simulate SARS-CoV-2 transmission in a long-term care facility with varying COVID-19 containment measures in place (social distancing, face masks, vaccination). In contrast to routine symptomatic testing using reverse-transcriptase polymerase chain reaction (RT-PCR), we evaluated the efficacy and health-economic efficiency of single or repeated population-wide Ag-RDT screening interventions implemented in response to surges in nosocomial outbreak risk.

Results Depending on the baseline containment measures in place, nosocomial SARS-CoV-2 incidence was reduced by up to 40-47% (range of means) with routine RT-PCR testing, 59-63% with the addition of a timely round of Ag-RDT screening, and 69-75% with well-timed two-round screening. For the latter, a delay of 4 to 5 days between the first and second rounds was optimal for transmission prevention. Efficacy varied depending on test sensitivity, subpopulations targeted, and SARS-CoV-2 incidence in the community. Efficiency, however, varied primarily depending on the other containment measures in place: surveillance costs for a combined strategy of routine RT-PCR testing and reactive Ag-RDT screening ranged from a mean €420-€10,260/infection averted across scenarios (default unit costs: €5/Ag-RDT test, €50/RT-PCR test).

Interpretation Reactive Ag-RDT screening complements routine RT-PCR testing, and systematic two-round screening helps overcome limited, time-varying diagnostic sensitivity. Health-economic gains scale significantly with underlying nosocomial outbreak risk.

Funding National Research Agency, Canadian Institutes of Health Research, Fondation de France

Competing Interest Statement

LO reports grants from Pfizer outside the submitted work. Authors report no other conflicts of interest.

Funding Statement

The work was supported directly by internal resources from the French National Institute for Health and Medical Research, the Institut Pasteur, the Conservatoire National des Arts et Metiers, and the University of Versailles-Saint-Quentin-en-Yvelines / University of Paris-Saclay. This study received funding from the French Government and its Investissement dAvenir program, Laboratoire dExcellence Integrative Biology of Emerging Infectious Diseases (Grant ANR-10-LABX-62- IBEID). DS is supported by a Canadian Institutes of Health Research Doctoral Foreign Study Award (Funding Reference Number 164263) as well as the French government through its National Research Agency project SPHINX-17-CE36-0008-01.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study used inter-individual contact data from the i-Bird study, which obtained all authorizations in accordance with French regulations regarding medical research and information processing. All French Institutional Review Board-equivalent agencies gave the i-Bird program official approval (Comités de protection des personnes 08061; Agence française de sécurité sanitaire des produits de santé 2008-A01284-51; Comité consultatif sur le traitement de l'information en matière de recherche 08.533; Commission nationale de l'informatique et des libertés reference number AT/YPA/SV/SN/GDP/AR091118, declaration number 909036). Signed consent by patients and staff was not required according to the French Ethics Committee to which the project was submitted.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Simulated data are available from authors upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rapid antigen testing as a reactive public health response to surges in SARS-CoV-2 outbreak risk in healthcare settings
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rapid antigen testing as a reactive public health response to surges in SARS-CoV-2 outbreak risk in healthcare settings
David R. M. Smith, Audrey Duval, Jean Ralph Zahar, Lulla Opatowski, Laura Temime
medRxiv 2021.08.13.21261968; doi: https://doi.org/10.1101/2021.08.13.21261968
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Rapid antigen testing as a reactive public health response to surges in SARS-CoV-2 outbreak risk in healthcare settings
David R. M. Smith, Audrey Duval, Jean Ralph Zahar, Lulla Opatowski, Laura Temime
medRxiv 2021.08.13.21261968; doi: https://doi.org/10.1101/2021.08.13.21261968

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (413)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (158)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8547)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1742)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1237)
  • Health Policy (619)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10279)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1669)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (926)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1762)
  • Public and Global Health (3832)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (319)
  • Respiratory Medicine (520)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (157)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (74)